American Skin Association announced that Dr. Mark Lebwohl, a leading expert in dermatology, has become a member of its Board of Directors.
NEW YORK, April 27, 2020 /PRNewswire/ -- American Skin Association (ASA) today announced that Dr. Mark Lebwohl, a leading expert in dermatology, has become a member of its Board of Directors. Dr. Lebwohl is the Waldman Professor and Chair of the Kimberly and Eric J. Waldman Department of Dermatology of the Icahn School of Medicine at Mount Sinai in New York. He is past President of the American Academy of Dermatology. Dr. Lebwohl’s decades of experience bring a unique perspective to the ASA Board. He will be honored with the ASA Distinguished Leadership Award at the organization’s upcoming Annual Gala in the fall.
“I am very proud to announce the addition of Dr. Mark Lebwohl to ASA’s Board of Directors. He will be a tremendous asset in helping us serve our dual missions of funding cutting-edge research and educating the public on the importance of skin health and sun safety,” said Howard P. Milstein, Chairman of ASA.
“Dr. Lebwohl is a wonderful addition to the ASA Board! I look forward to working with him as we continue to fund vital research in the hope to find for those suffering from skin diseases,” said President of ASA, Dr. David Norris.
Dr. Lebwohl graduated summa cum laude from Columbia College in 1974 and graduated from Harvard Medical School in 1978. He completed residencies in internal medicine and dermatology, both at Mount Sinai, and has been practicing dermatology since 1983.
Dr. Lebwohl is chairman emeritus of the Medical Board of the National Psoriasis Foundation. He has served on the editorial board of the Journal of the American Academy of Dermatology and has served as editor of the Dermatology Section of Scientific American Medicine.
He has chaired numerous symposia and has written, edited, or co-edited several books, including the first atlas devoted entirely to cutaneous manifestations of systemic disease, and the leading book on dermatologic therapy, Treatment of Skin Disease. The second edition of The Skin and Systemic Disease has been published in English and in French, while Treatment of Skin Disease, now in its fifth edition with a sixth in development, has been published in English, Chinese, Portuguese, Spanish, and Polish. Other books by Dr. Lebwohl include Difficult Diagnoses in Dermatology, Psoriasis, Mild-to-Moderate Psoriasis and Moderate-to-Severe Psoriasis. He has authored or co-authored over 500 peer-reviewed articles, and many invited articles and book chapters.
Dr. Lebwohl is actively involved in clinical trials of many new dermatologic treatments. He introduced the use of imiquimod for the treatment of actinic keratosis; the use of topical calcineurin inhibitors for facial and intertriginous psoriasis; and many topical, systemic and combination therapies for psoriasis.
ABOUT AMERICAN SKIN ASSOCIATION
ASA is a unique collaboration of patients, families, advocates, physicians and scientists, and has evolved over thirty-one years into a leading force in efforts to defeat melanoma, skin cancer and important inflammatory and genetic skin diseases. Established to serve the now more than 100 million Americans – one third of the U.S. population – afflicted with skin disorders, the organization’s mission remains to: advance research, champion skin health – particularly among children, and drive public awareness about skin disease. For more information, visit americanskin.org.
View original content:http://www.prnewswire.com/news-releases/american-skin-association-announces-new-board-member-mark-lebwohl-md-301047837.html
SOURCE American Skin Association
